Studymoderate evidence
Responsiveness of epigenetic aging biomarkers to longevity interventions in humans.
Nature medicine·August 21, 2026·PMID 42629466
Why it mattersSelecting responsive DNA methylation biomarkers is critical for designing efficient longevity trials, as surrogate endpoints could dramatically shorten study timelines. This analysis identifies which clocks and interventions yield the most robust signals, guiding future trial design and biomarker selection.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled